What the FDA labels say about taking them together
Relugolix and testosterone
Relugolix's FDA label of October 10, 2025 names testosterone in its warnings and precautions section; the testosterone labels PlainMeds reads (4) do not name relugolix. The relugolix label: “If PSA increases, serum concentrations of testosterone should be measured.”
Check it at the source: the relugolix FDA label on DailyMed (effective October 10, 2025, Sumitomo Pharma America, Inc.); the testosterone FDA label on DailyMed (effective July 25, 2025, Azurity Pharmaceuticals, Inc.).
What does the relugolix label say about testosterone?
Relugolix label, warnings and precautionsIf PSA increases, serum concentrations of testosterone should be measured.
Source: FDA drug label (Orgovyx), Sumitomo Pharma America, Inc., effective October 10, 2025 (SPL set 077a92f6-9f1b-479a-87c7-c92b5db6aa9c), via openFDA; the full label on DailyMed
What does the testosterone label say about relugolix?
Testosterone's label (effective July 25, 2025) and its 3 other brand-application labels do not name relugolix in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AZMIRO), Azurity Pharmaceuticals, Inc., effective July 25, 2025 (SPL set 235b5625-570d-3fba-e063-6394a90aa2d1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Relugolix | Testosterone | |
|---|---|---|
| Labeled for | Prostate cancer | Breast cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $11.39 per mL 200 mg/mL |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once